Publicaciones en colaboración con investigadores/as de Hospital Universitario Virgen Macarena (32)

2024

  1. Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies

    Journal of neurology, Vol. 271, Núm. 1, pp. 472-485

  2. Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis

    Journal of Neurology, Neurosurgery and Psychiatry, Vol. 95, Núm. 5, pp. 410-418

2023

  1. Comparative effectiveness in multiple sclerosis: A methodological comparison

    Multiple Sclerosis Journal, Vol. 29, Núm. 3, pp. 326-332

  2. Detecting disability using self-reported and clinical assessments in early-stage relapsing-remitting multiple sclerosis: Looking for a complementary approach

    Multiple Sclerosis Journal - Experimental, Translational and Clinical, Vol. 9, Núm. 2

  3. Disability accrual in primary and secondary progressive multiple sclerosis

    Journal of Neurology, Neurosurgery and Psychiatry, Vol. 94, Núm. 9, pp. 707-717

  4. Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis

    Multiple sclerosis (Houndmills, Basingstoke, England), Vol. 29, Núm. 7, pp. 875-883

  5. Effectiveness and Safety of Teriflunomide in Relapsing–Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study

    Neurology and Therapy, Vol. 12, Núm. 6, pp. 2177-2193

  6. Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial

    Journal of neurology, neurosurgery, and psychiatry, Vol. 94, Núm. 12, pp. 1004-1011

  7. Hopelessness in Patients with Early-Stage Relapsing-Remitting Multiple Sclerosis

    Patient Preference and Adherence, Vol. 17, pp. 1431-1439

  8. The risk of secondary progressive multiple sclerosis is geographically determined but modifiable

    Brain : a journal of neurology, Vol. 146, Núm. 11, pp. 4633-4644

  9. Variability of the response to immunotherapy among subgroups of patients with multiple sclerosis

    European Journal of Neurology, Vol. 30, Núm. 4, pp. 1014-1024

2022

  1. Confirmed disability progression as a marker of permanent disability in multiple sclerosis

    European Journal of Neurology, Vol. 29, Núm. 8, pp. 2321-2334

  2. Delayed cognitive processing and treatment status quo bias in early-stage multiple sclerosis

    Multiple Sclerosis and Related Disorders, Vol. 68

  3. Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis

    Neurology, Vol. 99, Núm. 17, pp. E1926-E1944

  4. Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network

    Journal of Neurology, Neurosurgery and Psychiatry, Vol. 94, Núm. 1, pp. 23-30

  5. Identification of the genetic mechanism that associates L3MBTL3 to multiple sclerosis

    Human Molecular Genetics, Vol. 31, Núm. 13, pp. 2155-2163

  6. Long-term prognosis communication preferences in early-stage relapsing-remitting multiple sclerosis

    Multiple Sclerosis and Related Disorders, Vol. 64

  7. Measuring productivity loss in early relapsing-remitting multiple sclerosis

    Multiple Sclerosis and Related Disorders, Vol. 58

2021

  1. Determinants of therapeutic lag in multiple sclerosis

    Multiple Sclerosis Journal, Vol. 27, Núm. 12, pp. 1838-1851

  2. Natalizumab, Fingolimod, and Dimethyl Fumarate Use and Pregnancy-Related Relapse and Disability in Women With Multiple Sclerosis

    Neurology, Vol. 96, Núm. 24, pp. E2989-E3002